These cell lines, which harbour different oncogenic drivers (e.g. A549, mutant KRAS; H1299, mutant NRAS; H1944, mutant KRAS; H2228, WT KRAS; H460, mutant KRAS; H358 mutant KRAS; and H1795, WT KRAS) and distinct NRF2/KEAP1 statuses (A549, H1944, H2228 and H460 are mutant KEAP1, while H1299, H358 and H1795 are WT KEAP1) demonstrated that the signature performs well in a variety of lung cancer cells. This evidence concerns the gene KEAP1 and lung cancer.